13 Analysts Have This To Say About Teva Pharmaceutical Indus
Teva Pharmaceutical Indus (NYSE:TEVA) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 6 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 3 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $37.38, with a high estimate of $45.00 and a low estimate of $31.00. Surpassing the previous average price target of $32.27, the current average has increased by 15.84%.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Teva Pharmaceutical Indus is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Les Sulewski | Truist Securities | Raises | Buy | $42.00 | $38.00 |
| Matt Dellatorre | Goldman Sachs | Raises | Buy | $45.00 | $36.00 |
| Glen Santangelo | Barclays | Raises | Overweight | $38.00 | $35.00 |
| Louise Chen | Scotiabank | Raises | Sector Outperform | $40.00 | $35.00 |
| Les Sulewski | Truist Securities | Raises | Buy | $38.00 | $36.00 |
| Glen Santangelo | Jefferies | Raises | Buy | $40.00 | $29.00 |
| David Amsellem | Piper Sandler | Raises | Overweight | $40.00 | $30.00 |
| Matt Dellatorre | Goldman Sachs | Raises | Buy | $35.00 | $31.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $35.00 | $28.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $32.00 | $29.00 |
| Glen Santangelo | Barclays | Announces | Overweight | $35.00 | - |
| Matt Dellatorre | Goldman Sachs | Raises | Buy | $31.00 | $28.00 |
| Louise Chen | Scotiabank | Announces | Sector Outperform | $35.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teva Pharmaceutical Indus. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Teva Pharmaceutical Indus's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teva Pharmaceutical Indus's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Teva Pharmaceutical Indus analyst ratings.
All You Need to Know About Teva Pharmaceutical Indus
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Unraveling the Financial Story of Teva Pharmaceutical Indus
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Teva Pharmaceutical Indus's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2025, the company achieved a revenue growth rate of approximately 11.4%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 10.19%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Teva Pharmaceutical Indus's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.33%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Teva Pharmaceutical Indus's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.19%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Teva Pharmaceutical Indus's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.16, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Analyst Ratings: Simplified
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.